Search Results Search Sort by RelevanceMost Recent Podcast May 2019 Ethics Talk: When and How Should ECMO Be Initiated and Removed? When should ECMO be started and stopped? This month’s Ethics Talk explores ethical challenges of ECMO use in end-of-life care. Case and Commentary Oct 2019 How Should Decision Science Inform Scarce Blood Product Allocation? Eric Kersjes, MD and Lauren B. Smith, MD Decision aids could help clinicians know when to request ethics consultation or re-evaluate blood product usage in a specific patient care situation. AMA J Ethics. 2019;21(10):E852-857. doi: 10.1001/amajethics.2019.852. Medicine and Society Oct 2019 How Should Decision Aids Be Used During Counseling to Help Patients Who Are “Genetically at Risk”? Natalie Evans, PhD, Suzanne Metselaar, PhD, Carla van El, PhD, Nina Hallowell, DPhil, MA, and Guy Widdershoven, PhD Prognostic uncertainty about risk creates demand for ongoing communication and facilitated reflection about goals and values. AMA J Ethics. 2019;21(10):E865-872. doi: 10.1001/amajethics.2019.865. Case and Commentary Jul 2019 Should Dialysis Be Stopped for an Unrepresented Patient With Metastatic Cancer? Adira Hulkower, JD, MS, Sarah Garijo-Garde, and Lauren S. Flicker, JD, MBE Legal inconsistencies and variation in end-of-life options generate disparities in care for unrepresented patients. AMA J Ethics. 2019;21(7):E575-581. doi: 10.1001/amajethics.2019.575. AMA Code Says Jul 2019 AMA Code of Medical Ethics’ Opinions Related to Unrepresented Patients Danielle Hahn Chaet, MSB The AMA Code of Medical Ethics discusses situations in which a surrogate is needed but not available to make health care decisions for a patient. AMA J Ethics. 2019;21(7):E600-602. doi: 10.1001/amajethics.2019.600. State of the Art and Science Apr 2016 Keeping the Backdoor to Eugenics Ajar?: Disability and the Future of Prenatal Screening Gareth M. Thomas, PhD and Barbara Katz Rothman, PhD Noninvasive prenatal testing arguably constitutes a form of eugenics in a social context in which certain reproductive outcomes are not valued. AMA J Ethics. 2016;18(4):406-415. doi: 10.1001/journalofethics.2016.18.4.stas1-1604. Viewpoint Sep 2016 The Limits of Informed Consent for an Overwhelmed Patient: Clinicians’ Role in Protecting Patients and Preventing Overwhelm Johan Bester, MBChB, MPhil, Cristie M. Cole, JD, and Eric Kodish, MD Protecting patients rather than informed consent should be the goal when the complexity of information overwhelms patients’ decision-making capacity. AMA J Ethics. 2016;18(9):869-886. doi: 10.1001/journalofethics.2016.18.9.peer2-1609. Case and Commentary Jan 2006 Presymptomatic Genetic Testing for ALS Leo McCluskey, MD, MBe Virtual Mentor. 2006;8(1):16-19. doi: 10.1001/virtualmentor.2006.8.1.ccas2-0601. Case and Commentary Feb 2005 Quality of Life and Prenatal Decisions, Commentary 1 Ludger Schols, MD Virtual Mentor. 2005;7(2):136-140. doi: 10.1001/virtualmentor.2005.7.2.ccas1-0502. Case and Commentary Feb 2005 Quality of Life and Prenatal Decisions, Commentary 2 Georg Marckmann, MD Virtual Mentor. 2005;7(2):136-140. doi: 10.1001/virtualmentor.2005.7.2.ccas1-0502. Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Next page Next › Last page Last »
Podcast May 2019 Ethics Talk: When and How Should ECMO Be Initiated and Removed? When should ECMO be started and stopped? This month’s Ethics Talk explores ethical challenges of ECMO use in end-of-life care.
Case and Commentary Oct 2019 How Should Decision Science Inform Scarce Blood Product Allocation? Eric Kersjes, MD and Lauren B. Smith, MD Decision aids could help clinicians know when to request ethics consultation or re-evaluate blood product usage in a specific patient care situation. AMA J Ethics. 2019;21(10):E852-857. doi: 10.1001/amajethics.2019.852.
Medicine and Society Oct 2019 How Should Decision Aids Be Used During Counseling to Help Patients Who Are “Genetically at Risk”? Natalie Evans, PhD, Suzanne Metselaar, PhD, Carla van El, PhD, Nina Hallowell, DPhil, MA, and Guy Widdershoven, PhD Prognostic uncertainty about risk creates demand for ongoing communication and facilitated reflection about goals and values. AMA J Ethics. 2019;21(10):E865-872. doi: 10.1001/amajethics.2019.865.
Case and Commentary Jul 2019 Should Dialysis Be Stopped for an Unrepresented Patient With Metastatic Cancer? Adira Hulkower, JD, MS, Sarah Garijo-Garde, and Lauren S. Flicker, JD, MBE Legal inconsistencies and variation in end-of-life options generate disparities in care for unrepresented patients. AMA J Ethics. 2019;21(7):E575-581. doi: 10.1001/amajethics.2019.575.
AMA Code Says Jul 2019 AMA Code of Medical Ethics’ Opinions Related to Unrepresented Patients Danielle Hahn Chaet, MSB The AMA Code of Medical Ethics discusses situations in which a surrogate is needed but not available to make health care decisions for a patient. AMA J Ethics. 2019;21(7):E600-602. doi: 10.1001/amajethics.2019.600.
State of the Art and Science Apr 2016 Keeping the Backdoor to Eugenics Ajar?: Disability and the Future of Prenatal Screening Gareth M. Thomas, PhD and Barbara Katz Rothman, PhD Noninvasive prenatal testing arguably constitutes a form of eugenics in a social context in which certain reproductive outcomes are not valued. AMA J Ethics. 2016;18(4):406-415. doi: 10.1001/journalofethics.2016.18.4.stas1-1604.
Viewpoint Sep 2016 The Limits of Informed Consent for an Overwhelmed Patient: Clinicians’ Role in Protecting Patients and Preventing Overwhelm Johan Bester, MBChB, MPhil, Cristie M. Cole, JD, and Eric Kodish, MD Protecting patients rather than informed consent should be the goal when the complexity of information overwhelms patients’ decision-making capacity. AMA J Ethics. 2016;18(9):869-886. doi: 10.1001/journalofethics.2016.18.9.peer2-1609.
Case and Commentary Jan 2006 Presymptomatic Genetic Testing for ALS Leo McCluskey, MD, MBe Virtual Mentor. 2006;8(1):16-19. doi: 10.1001/virtualmentor.2006.8.1.ccas2-0601.
Case and Commentary Feb 2005 Quality of Life and Prenatal Decisions, Commentary 1 Ludger Schols, MD Virtual Mentor. 2005;7(2):136-140. doi: 10.1001/virtualmentor.2005.7.2.ccas1-0502.
Case and Commentary Feb 2005 Quality of Life and Prenatal Decisions, Commentary 2 Georg Marckmann, MD Virtual Mentor. 2005;7(2):136-140. doi: 10.1001/virtualmentor.2005.7.2.ccas1-0502.